Generalised anxiety disorder: treatment options

Area of Science:

• Psychiatry and Clinical Psychology
• Pharmacology and Therapeutics

Background:

• Generalised Anxiety Disorder (GAD) is increasingly well-defined but receives less attention than panic or social phobia.
• Historically, benzodiazepines were the primary treatment for GAD, but concerns over abuse potential led to exploring alternatives.

Purpose of the Study:

• To review the evolution and current landscape of GAD treatment options.
• To discuss the efficacy and limitations of existing pharmacotherapies and psychotherapies.
• To highlight emerging treatments and future research directions in GAD management.

Main Methods:

• Literature review of clinical trials and pharmacological studies on GAD treatments.
• Analysis of treatment efficacy, adverse effect profiles, and patient outcomes.
• Examination of current and investigational pharmacotherapeutic agents.

Main Results:

• Benzodiazepines are effective for short-term GAD management; buspirone and antidepressants are preferred for long-term treatment.
• Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), show efficacy and good tolerability.
• Psychotherapy can be a beneficial adjunct to pharmacotherapy.

Conclusions:

• Current GAD treatment relies on established pharmacotherapies and psychotherapy, with a shift towards antidepressants for long-term care.
• While novel pharmacotherapies are under investigation, none are expected soon, necessitating continued research for optimal anxiolytic development.
• Future research holds promise for developing more effective and targeted treatments for GAD.